Berberine
Berberine is a plant alkaloid (from Berberis and related species) taken as a supplement for glucose control, lipids and general metabolic support, sometimes dubbed 'natural metformin'. PED users use it on cycle for insulin sensitivity and lipid support and off cycle as a metabolic aid. Human data are moderate for glycaemia and lipids but limited by poor bioavailability and variable study quality.
01 Overview
Berberine activates AMP-activated protein kinase (AMPK), a central metabolic sensor, which improves insulin signalling, reduces hepatic glucose output and modulates lipid synthesis. Meta-analyses of small trials show reductions in fasting glucose, HbA1c, total and LDL cholesterol and triglycerides, sometimes approaching the effect of low-dose metformin, though studies are heterogeneous.
Among PED users it is used to support insulin sensitivity during growth-oriented or high-carbohydrate phases and to help offset steroid- or GH-related lipid and glucose shifts. Its very poor oral bioavailability means high, divided doses are needed, and GI upset is the main limiting factor. It also inhibits CYP3A4 and P-glycoprotein, creating real potential for drug interactions.
02 Mechanism
Activates AMPK, improving insulin sensitivity, lowering hepatic gluconeogenesis and modulating lipid metabolism; also alters gut microbiota and inhibits CYP3A4/P-glycoprotein.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Lower supplemental use | 500–900 mg/day | Oral | Starting range to gauge GI tolerance. |
| Metabolic / glucose support | 900–1500 mg/day | Oral | Typically 3 x 500 mg with meals owing to poor bioavailability. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Improved glucose controlLowers fasting glucose and HbA1c in small trials, sometimes comparable to low-dose metformin. | modest | Observational | |
| Improved lipidsReductions in LDL cholesterol and triglycerides reported across meta-analyses of small studies. | modest | Observational |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Gastrointestinal upsetDiarrhoea, constipation, cramping and nausea, especially early on. | Mild | Common | Observational | |
| Drug interactions (CYP3A4 / P-gp)Can raise levels of co-administered drugs metabolised by CYP3A4 or transported by P-glycoprotein. | Moderate | Situational | Preclinical |